Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized Controlled Clinical Trial Evaluating the Efficacy of Silverlon® in Preventing Surgical Site Infection Following Colorectal Surgery
Brief Summary: This clinical study is a prospective, randomized, controlled trial of patients undergoing elective colorectal surgical procedures that receive an abdominal skin incision of at least 6 cm. Treatment with Silverlon® will be compared to standard postoperative dressings of 4x4 Gauze and paper tape. Patients will be randomized with a 1:1 treatment allocation ratio to receive either 1) Silverlon® or 2) standard postsurgical dressing. Neither the Investigators nor the participants will be blinded to the treatment modality after randomization.

Silver has long been known to have antimicrobial properties. It interacts with structural proteins and DNA, inhibiting bacterial replication and causing fatal structural changes within the cell wall. It has broad antimicrobial activities and unlike antibiotics, it is rarely associated with microbial resistance. Silverlon® is a silver-nylon dressing specifically designed for surgical wounds to prevent the development of surgical site infections. It is an easy to use product with no known microbial resistance or adverse effects. The efficacy of Silverlon® in preventing surgical site infections has been shown in several retrospective studies but as of yet has not been tested in a prospective fashion. The objective of this study is to perform a prospective, randomized, clinical trial directly comparing the incidence of surgical site infections in patients treated with Silverlon® to standard postoperative dressing following elective colorectal surgery


Options:
A: Inclusion Criteria:

1. All patients undergoing elective colorectal surgery by a trained colorectal surgeon with an abdominal skin incision of at least 3 cm
2. Patients that are willing and able to comply with the requirements of the protocol including follow-up requirements
3. Patients willing and able to sign a study specific informed consent

Exclusion Criteria:

1. Patients that fail to meet the skin incision size criteria
2. Patients with a known allergy to silver
3. Patients less than 18 years of age
4. Any contraindication to undergoing a surgical procedure under general anesthesia
5. Patients with preoperative evidence of a current abdominal wall infection/surgical site infection from a previous laparotomy/laparoscopy
6. Patients that have received antibiotic therapy within the week prior to surgery
7. Patients with preoperative evaluation suggestive of an intra-abdominal process that would preclude full closure of the skin
8. Patients with a previously placed anterior abdominal wall mesh that is not planned to be completely removed during the planned procedure
9. Women who are pregnant or breast feeding or are considering becoming pregnant during the follow-up period
10. Mental incompetence as determined by the Investigator which would affect participation in the study
11. Concurrently participating in any other investigational study
B: Inclusion Criteria:

* Diagnosis of colorectal neoplasms and plans to undergo an elective surgery with curative aims.
* Open surgical approach

Exclusion Criteria:

* Anastomotic leak
* Mortality
* Lost to follow-up
C: Inclusion Criteria:

* Subject has a cataract and is expected to undergo unilateral clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber monofocal intraocular lens through an incision ≤ 3.5mm in width measured after IOL implantation using internal calipers.

Exclusion Criteria:

* Any intraocular inflammation in the study eye that was present during the screening slit-lamp examination or presence of ocular pain in the operative eye as rated on the pre-operative NRPS
* Previous surgery (laser or incisional) or ocular trauma to the operative eye or planned multiple procedures during cataract/IOL implantation surgery
* Potential BCVA in fellow eye worse than 20/40 as assessed by the clinical Investigator
* Active or history of chronic or recurrent inflammatory eye disease (iritis, scleritis, uveitis, iridocyclitis, rubeosis iritis), evidence of acute external ocular infections, intraocular infection, dysthyroid ophthalmopathy, nasolacrimal duct obstruction, active chalazion, uncontrolled blepharitis, uncontrolled and clinically significant dry eye syndrome, anything more than trace guttata (\>10 guttae in the central 6 mm of cornea), evidence of glaucoma/glaucoma suspect, corneal dystrophy or other ocular disease that would interfere with study evaluations
* Subject is currently receiving antineoplastic therapy
* Use of topical ocular steroids within 14 days and/or systemic steroids (excluding inhalants) within 30 days prior to surgery.
* Subject is an insulin-dependent diabetic or has background diabetic retinopathy (BDR), proliferative diabetic retinopathy (PDR) or compromised macular function
D: Inclusion Criteria:

* Patients bearing solid tumours who are candidate to open radical surgery for colorectal cancer (histology proven)
* Age 18-75
* Informed signed consent
* Performance Status 0-2 (according to ECOG score)
* Platelets \> 50.000/mm3
* Prothrombin Time (Quick) \> 60%
* White Blood Cells \> 2500/mm3
* Life Expectancy \> 3 months

Exclusion Criteria:

* Intestinal obstruction
* Severe intestinal bleeding requiring blood transfusion
* Age under 18 or over 75
* Severe hepatic failure (ascites, portal hypertension, jaundice or encephalopathy)
* Renal failure (hemodialysis, creatinin \> 2.5 mg/dL)
* Active infections
* Coagulopathy
* Inability to give an informed consent
* Known allergies to dressing components

Answer: A